<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38011560</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>49</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.</ArticleTitle><Pagination><StartPage>e2305772120</StartPage><MedlinePgn>e2305772120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2305772120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2305772120</ELocationID><Abstract><AbstractText>Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and protection against relapse distinguish it from prior antidepressants. Its discovery emerged from a reconceptualization of the neurobiology of depression and, in turn, insights from the elaboration of its mechanisms of action inform studies of the pathophysiology of depression and related disorders. It has been 25 y since we first presented our ketamine findings in depression. Thus, it is timely for this review to consider what we have learned from studies of ketamine and to suggest future directions for the optimization of rapid-acting antidepressant treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krystal</LastName><ForeName>John H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-6952-1726</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry and Behavioral Health Services, Yale-New Haven Hospital, New Haven, CT 06510.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroscience Division, National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Alfred P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroscience Division, National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroscience Division, National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girgenti</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroscience Division, National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Samuel T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry and Behavioral Health Services, Yale-New Haven Hospital, New Haven, CT 06510.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanacora</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry and Behavioral Health Services, Yale-New Haven Hospital, New Haven, CT 06510.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esterlis</LastName><ForeName>Irina</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-6293-1458</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroscience Division, National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH129371</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="Y">Ketamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antidepressant</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">ketamine</Keyword><Keyword MajorTopicYN="N">neuroplasticity</Keyword><Keyword MajorTopicYN="N">stress</Keyword></KeywordList><CoiStatement>Competing interests statement:S.T.W.: Janssen Research Foundation, Sage Therapeutics; J.H.K.: (consultations less than $5,000/y) Aptinyx, Inc., BioXcel, Biogen, Idec, MA, Bionomics, Limited (Australia), Boehringer Ingelheim International, Cerevel Pharmaceuticals, Epiodyne, Inc., Esai, Inc., Janssen Research &amp; Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., PsychoGenics, Inc., Sunovion Pharmaceuticals, Inc., Takeda Pharmaceuticals (Stock/Options) Biohaven Pharmaceuticals, Cartego Therapeutics, Damona Pharmaceuticals, Delix Therapeutics, Inc., EpiVario, Inc., Freedom Biosciences, Neumora Therapeutics, Inc., Response Pharmaceuticals, Rest Therapeutics, Spring Health, Inc., Tempero Bio, Inc., Terran Biosciences, Tetricus Inc. (nonmonetary support, i.e., provision of drug) Cerevel Pharmaceuticals, Novartis. G.S. has served as consultant to Ancora, Aptinyx, Atai, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Clexio, Cowen, Denovo Biopharma, ECR1, EMA Wellness, Engrail Therapeutics, Freedom Biosciences, Gilgamesh, Intra-Cellular Therapies, Janssen, KOA Health, Levo therapeutics, Lundbeck, Merck, MiCure, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Relmada Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Valeant, Vistagen Therapeutics, and XW Labs. G.S. holds equity in Biohaven Pharmaceuticals, Freedom Biosciences, Gilead, Relmada, and Tetricus. J.H.K. stands to benefit from patents held by Yale University that were licensed to Janssen Pharmaceuticals (ketamine), Biohaven Pharmaceuticals (riluzole), Freedom Biosciences (NMDA-R antagonist plus MTORC inhibitor), and Spring Health (precision medicine strategy). G.S. is a co-inventor on a US patent (#8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application No. 047162-7177P1 (00754) licensed to Janssen Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>15</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38011560</ArticleId><ArticleId IdType="pmc">PMC10710048</ArticleId><ArticleId IdType="doi">10.1073/pnas.2305772120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Domino E. F., Chodoff P., Corssen G., Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharm. Ther. 6, 279&#x2013;291 (1965).</Citation><ArticleIdList><ArticleId IdType="pubmed">14296024</ArticleId></ArticleIdList></Reference><Reference><Citation>Noppers I., et al. , Ketamine for the treatment of chronic non-cancer pain. Expert Opin. Pharmacother. 11, 2417&#x2013;2429 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20828267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R. F., Eccleston C., Kalso E. A., Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst. Rev. 11, CD003351 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">12535471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright M., Pharmacologic effects of ketamine and its use in veterinary medicine. J. Am. Vet. Med. Assoc. 180, 1462&#x2013;1471 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6124527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S. H., Tse M. L., Ng H. W., Lau F. L., Emergency department presentation of ketamine abusers in Hong Kong: A review of 233 cases. Hong Kong Med. J. 16, 6&#x2013;11 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20124567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W. K., et al. , Psychiatric morbidity in ketamine users attending counselling and youth outreach services. Subst. Abus 36, 67&#x2013;74 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25023206</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamar J. J., Rutherford C., Keyes K. M., Trends in ketamine use, exposures, and seizures in the United States. Am. J. Public Health 111, 2046&#x2013;2049 (2021), 10.2105/ajph.2021.306486.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.2021.306486</ArticleId><ArticleId IdType="pmc">PMC8630483</ArticleId><ArticleId IdType="pubmed">34618543</ArticleId></ArticleIdList></Reference><Reference><Citation>Muetzelfeldt L., et al. , Journey through the K-hole: Phenomenological aspects of ketamine use. Drug Alcohol. Depend. 95, 219&#x2013;229 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18355990</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., et al. , Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen. Psychiatr y 51, 199&#x2013;214 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8122957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahti A. C., Holcomb H. H., Medoff D. R., Tamminga C. A., Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6, 869&#x2013;872 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7612873</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra A. K., et al. , NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14, 301&#x2013;307 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8703299</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter W. T. Jr., The schizophrenia ketamine challenge study debate. Biol. Psychiatry 46, 1081&#x2013;1091 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10536744</ArticleId></ArticleIdList></Reference><Reference><Citation>Schatzberg A. F., A word to the wise about ketamine. Am. J. Psychiatry 171, 262&#x2013;264 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24585328</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomer H. P., Saunders J. C., Kline N. S., A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatric Res. Rep. 8, 129&#x2013;141 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13542681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn R., Treatment of depressive states with an iminodibenzyl derivative (G 22355). Schweiz. Med. Wochenschr. 87, 1135&#x2013;1140 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13467194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cade J. F., Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 2, 349&#x2013;352 (1949).</Citation><ArticleIdList><ArticleId IdType="pubmed">18142718</ArticleId></ArticleIdList></Reference><Reference><Citation>Delay J., Deniker P., Harl J. M., Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Ann. Med. Psychol. (Paris) 110, 112&#x2013;117 (1952).</Citation><ArticleIdList><ArticleId IdType="pubmed">12986408</ArticleId></ArticleIdList></Reference><Reference><Citation>Schildkraut J. J., Kety S. S., Biogenic amines and emotion. Science 156, 21&#x2013;37 (1967).</Citation><ArticleIdList><ArticleId IdType="pubmed">5335690</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppen A. J., Depressed states and indolealkylamines. Adv. Pharmacol. 1962, 283&#x2013;291 (1968).</Citation><ArticleIdList><ArticleId IdType="pubmed">5301640</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., Abdallah C. G., Sanacora G., Charney D. S., Duman R. S., Ketamine: A paradigm shift for depression research and treatment. Neuron 101, 774&#x2013;778 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560624</ArticleId><ArticleId IdType="pubmed">30844397</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomon R. M., Miller H. L., Krystal J. H., Heninger G. R., Charney D. S., Lack of behavioral effects of monoamine depletion in healthy subjects. Biol. Psychiatry 41, 58&#x2013;64 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">8988796</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmaal L., et al. , ENIGMA MDD: Seven years of global neuroimaging studies of major depression through worldwide data sharing. Trans. Psychiatry 10, 172 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260219</ArticleId><ArticleId IdType="pubmed">32472038</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrough J. W., et al. , Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Hum. Brain Mapp. 37, 3214&#x2013;3223 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980239</ArticleId><ArticleId IdType="pubmed">27144347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser R. H., Andrews-Hanna J. R., Wager T. D., Pizzagalli D. A., Large-scale network dysfunction in major depressive disorder: A meta-analysis of resting-state functional connectivity. JAMA Psychiatry 72, 603&#x2013;611 (2015), 10.1001/jamapsychiatry.2015.0071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2015.0071</ArticleId><ArticleId IdType="pmc">PMC4456260</ArticleId><ArticleId IdType="pubmed">25785575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayberg H. S., Limbic-cortical dysregulation: A proposed model of depression. J. Neuropsychiatry Clin. Neurosci. 9, 471&#x2013;481 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9276848</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzagalli D. A., Toward a better understanding of the mechanisms and pathophysiology of anhedonia: Are we ready for translation? Am. J. Psychiatry 179, 458&#x2013;469 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9308971</ArticleId><ArticleId IdType="pubmed">35775159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ressler K. J., Mayberg H. S., Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic. Nat. Neurosci. 10, 1116&#x2013;1124 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2444035</ArticleId><ArticleId IdType="pubmed">17726478</ArticleId></ArticleIdList></Reference><Reference><Citation>Scangos K. W., et al. , Closed-loop neuromodulation in an individual with treatment-resistant depression. Nat. Med. 27, 1696&#x2013;1700 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11219029</ArticleId><ArticleId IdType="pubmed">34608328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaker R. C., et al. , Post-mortem molecular profiling of three psychiatric disorders. Genome Med. 9, 72 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5534072</ArticleId><ArticleId IdType="pubmed">28754123</ArticleId></ArticleIdList></Reference><Reference><Citation>Labont&#xe9; B., et al. , Sex-specific transcriptional signatures in human depression. Nat. Med. 23, 1102&#x2013;1111 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734943</ArticleId><ArticleId IdType="pubmed">28825715</ArticleId></ArticleIdList></Reference><Reference><Citation>Girgenti M. J., et al. , Transcriptomic organization of the human brain in post-traumatic stress disorder. Nat. Neurosci. 24, 24&#x2013;33 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33349712</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins-de-Souza D., et al. , Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Trans. Psychiatry 2, e87 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309534</ArticleId><ArticleId IdType="pubmed">22832852</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., et al. , Functional annotation of the human PTSD methylome identifies tissue-specific epigenetic variation across subcortical brain regions. medRxiv [Preprint] (2023). 10.1101/2023.04.18.23288704 (Accessed 25 April 2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.18.23288704</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., et al. , Glutamate and GABA systems as targets for novel antidepressant and mood stabilizing treatments. Mol. Psychiatry 7, S71&#x2013;S80 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11986998</ArticleId></ArticleIdList></Reference><Reference><Citation>Duman R. S., Sanacora G., Krystal J. H., Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 102, 75&#x2013;90 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450409</ArticleId><ArticleId IdType="pubmed">30946828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kangas E. S., Vuoriainen E., Lindeman S., Astikainen P., Auditory event-related potentials in separating patients with depressive disorders and non-depressed controls: A narrative review. Int. J. Psychophysiol. 179, 119&#x2013;142 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35839902</ArticleId></ArticleIdList></Reference><Reference><Citation>Averill L. A., et al. , Reduced energy per cycle, a marker of glutamatergic synaptic strength, in individuals diagnosed with PTSD and depression. medRxiv [Preprint] (2021). 10.1101/2023.04.18.23288704 (Accessed 25 April 2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.18.23288704</ArticleId></ArticleIdList></Reference><Reference><Citation>Magarinos A. M., McEwen B. S., Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: Involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 69, 89&#x2013;98 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8637636</ArticleId></ArticleIdList></Reference><Reference><Citation>Radley J. J., et al. , Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex 16, 313&#x2013;320 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">15901656</ArticleId></ArticleIdList></Reference><Reference><Citation>Duric V., et al. , Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int. J. Neuropsychopharmacol. 16, 69&#x2013;82 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3414647</ArticleId><ArticleId IdType="pubmed">22339950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H. J., et al. , Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat. Med. 18, 1413&#x2013;1417 (2012), 10.1038/nm.2886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2886</ArticleId><ArticleId IdType="pmc">PMC3491115</ArticleId><ArticleId IdType="pubmed">22885997</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes S. E., et al. , Lower synaptic density is associated with depression severity and network alterations. Nat. Commun. 10, 1529 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449365</ArticleId><ArticleId IdType="pubmed">30948709</ArticleId></ArticleIdList></Reference><Reference><Citation>Popoli M., Yan Z., McEwen B. S., Sanacora G., The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13, 22&#x2013;37 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3645314</ArticleId><ArticleId IdType="pubmed">22127301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham G. E., Bading H., Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682&#x2013;696 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948541</ArticleId><ArticleId IdType="pubmed">20842175</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkowska G., Stockmeier C. A., Astrocyte pathology in major depressive disorder: Insights from human postmortem brain tissue. Curr. Drug Targets 14, 1225&#x2013;1236 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799810</ArticleId><ArticleId IdType="pubmed">23469922</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina A., et al. , Glutamate transporters: A key piece in the glutamate puzzle of major depressive disorder. J. Psychiatr. Res. 47, 1150&#x2013;1156 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23706640</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman R. M., et al. , Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351&#x2013;354 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10686270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate C. A. Jr., et al. , A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856&#x2013;864 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16894061</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawad M. Y., et al. , The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: A systematic review and meta-analysis. Expert Opin. Drug Saf. 21, 841&#x2013;852 (2022), 10.1080/14740338.2022.2058488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2022.2058488</ArticleId><ArticleId IdType="pubmed">35387538</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahji A., Zarate C. A., Vazquez G. H., Efficacy and safety of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Expert Opin. Drug Saf. 21, 863&#x2013;866 (2022), 10.1080/14740338.2022.2047928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2022.2047928</ArticleId><ArticleId IdType="pmc">PMC9949988</ArticleId><ArticleId IdType="pubmed">35231204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaynes B. N., et al. , Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D. J. Clin. Psychopharmacol. 32, 114&#x2013;119 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22198447</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A., et al. , Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N. Engl. J. Med. 388, 2315&#x2013;2325 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37224232</ArticleId></ArticleIdList></Reference><Reference><Citation>Alnefeesi Y., et al. , Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review &amp; meta-analysis. J. Psychiatr Res. 151, 693&#x2013;709 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35688035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon H. J., et al. , Long-term safety and efficacy of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression- an asian sub-group analysis from the SUSTAIN-2 study. Clin. Psychopharmacol. Neurosci. 20, 70&#x2013;86 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813327</ArticleId><ArticleId IdType="pubmed">35078950</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly E. J., et al. , Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry 76, 893&#x2013;903 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551577</ArticleId><ArticleId IdType="pubmed">31166571</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueorguieva R., Chekroud A. M., Krystal J. H., Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: An individual patient-level data meta-analysis. The Lancet Psychiatry 4, 230&#x2013;237 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340978</ArticleId><ArticleId IdType="pubmed">28189575</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki N., et al. , Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: Interim results of the SUSTAIN-3 study. Neuropsychopharmacology 48, 1225&#x2013;1233 (2023), 10.1038/s41386-023-01577-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-023-01577-5</ArticleId><ArticleId IdType="pmc">PMC10267177</ArticleId><ArticleId IdType="pubmed">37173512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavalali E. T., Monteggia L. M., Rapid homeostatic plasticity and neuropsychiatric therapeutics. Neuropsychopharmacology 48, 54&#x2013;60 (2022), 10.1038/s41386-022-01411-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-022-01411-4</ArticleId><ArticleId IdType="pmc">PMC9700859</ArticleId><ArticleId IdType="pubmed">35995973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali F., et al. , Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. Nat. Commun. 11, 72&#x2013;72 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946708</ArticleId><ArticleId IdType="pubmed">31911591</ArticleId></ArticleIdList></Reference><Reference><Citation>Foga&#xe7;a M. V., et al. , Inhibition of GABA interneurons in the mPFC is sufficient and necessary for rapid antidepressant responses. Mol. Psychiatry 26, 3277&#x2013;3291 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8052382</ArticleId><ArticleId IdType="pubmed">33070149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhard D. M., et al. , GABA interneurons are the cellular trigger for ketamine&#x2019;s rapid antidepressant actions. J. Clin. Invest. 130, 1336&#x2013;1349 (2019), 10.1172/JCI130808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130808</ArticleId><ArticleId IdType="pmc">PMC7269589</ArticleId><ArticleId IdType="pubmed">31743111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothula S., et al. , Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Mol. Psychiatry 26, 5097&#x2013;5111 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32488125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchikami M., et al. , Optogenetic stimulation of infralimbic PFC reproduces ketamine&#x2019;s rapid and sustained antidepressant actions. Proc. Natl. Acad. Sci. U.S.A. 112, 8106&#x2013;8111 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491758</ArticleId><ArticleId IdType="pubmed">26056286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanos P., et al. , NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine. J. Neurosci. 43, 1038&#x2013;1050 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9908316</ArticleId><ArticleId IdType="pubmed">36596696</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N., et al. , mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959&#x2013;964 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3116441</ArticleId><ArticleId IdType="pubmed">20724638</ArticleId></ArticleIdList></Reference><Reference><Citation>Moda-Sava R. N., et al. , Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science (New York, N.Y.) 364, eaat8078 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6785189</ArticleId><ArticleId IdType="pubmed">30975859</ArticleId></ArticleIdList></Reference><Reference><Citation>Phoumthipphavong V., Barthas F., Hassett S., Kwan A. C., Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex. eNeuro 3 (2016), 10.1523/ENEURO.0133-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0133-15.2016</ArticleId><ArticleId IdType="pmc">PMC4819286</ArticleId><ArticleId IdType="pubmed">27066532</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah C. G., et al. , The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43, 2154&#x2013;2160 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6098048</ArticleId><ArticleId IdType="pubmed">29977074</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLorenzo C., et al. , In vivo ketamine-induced changes in [(1)(1)C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol. Psychiatry 77, 266&#x2013;275 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4277907</ArticleId><ArticleId IdType="pubmed">25156701</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes S. E., et al. , Measuring the effects of ketamine on mGluR5 using [(18)F]FPEB and PET. J. Cereb Blood Flow Metab 40, 2254&#x2013;2264 (2019), 10.1177/0271678x19886316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678x19886316</ArticleId><ArticleId IdType="pmc">PMC7585925</ArticleId><ArticleId IdType="pubmed">31744389</ArticleId></ArticleIdList></Reference><Reference><Citation>Esterlis I., et al. , Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: An [11C]ABP688 and PET imaging study in depression. Mol. Psychiatry 23, 824&#x2013;832 (2017), 10.1038/mp.2017.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.58</ArticleId><ArticleId IdType="pmc">PMC5636649</ArticleId><ArticleId IdType="pubmed">28397841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent A. C., et al. , Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol. Psychiatry 24, 1040&#x2013;1052 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6111001</ArticleId><ArticleId IdType="pubmed">29487402</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent A. C., Wills K. E., Gilbert J. R., Zarate C. A. Jr., Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study. Psychiatry Res. Neuroimaging 283, 64&#x2013;66 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410365</ArticleId><ArticleId IdType="pubmed">30551012</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah C. G., et al. , Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology 42, 1210&#x2013;1219 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437875</ArticleId><ArticleId IdType="pubmed">27604566</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes S. E., et al. , Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol. Psychiatry 27, 2273&#x2013;2281 (2022), 10.1038/s41380-022-01465-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01465-2</ArticleId><ArticleId IdType="pmc">PMC9133063</ArticleId><ArticleId IdType="pubmed">35165397</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., Sanacora G., Duman R. S., Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol. Psychiatry 73, 1133&#x2013;1141 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671489</ArticleId><ArticleId IdType="pubmed">23726151</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano G., Abbott L. F., Marder E., Activity-dependent changes in the intrinsic properties of cultured neurons. Science 264, 974&#x2013;977 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8178157</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano G. G., The dialectic of Hebb and homeostasis. Philos. Trans. R. Soc. Lond B Biol. Sci . 372, 20160258 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5247594</ArticleId><ArticleId IdType="pubmed">28093556</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado J. Y., Fink A. E., Grant S. G. N., O&#x2019;Dell T. J., Opazo P., Rapid homeostatic downregulation of LTP by extrasynaptic GluN2B receptors. J. Neurophysiol. 120, 2351&#x2013;2357 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6295522</ArticleId><ArticleId IdType="pubmed">30110236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. W., Suzuki K., Kavalali E. T., Monteggia L. M., Bridging rapid and sustained antidepressant effects of ketamine. Trends Mol. Med. 29, 275&#x2013;364 (2023), 10.1016/j.molmed.2023.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2023.02.003</ArticleId><ArticleId IdType="pmc">PMC10101916</ArticleId><ArticleId IdType="pubmed">36907686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. W., et al. , Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation. Nat. Neurosci. 24, 1100&#x2013;1109 (2021), 10.1038/s41593-021-00868-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00868-8</ArticleId><ArticleId IdType="pmc">PMC8338784</ArticleId><ArticleId IdType="pubmed">34183865</ArticleId></ArticleIdList></Reference><Reference><Citation>Buist M., et al. , Differential sensitivity of the protein translation initiation machinery and mTOR signaling to MECP2 gain- and loss-of-function involves MeCP2 isoform-specific homeostasis in the brain. Cells 11, 1442 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9105805</ArticleId><ArticleId IdType="pubmed">35563748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai K., Liu B., Teng J., MicroRNA-212-3p regulates early neurogenesis through the AKT/mTOR pathway by targeting MeCP2. Neurochem. Int. 137, 104734 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32246981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei E., Chen P., Zhang Q., Zhong Y., Zhou T., Protein kinase B/Akt1 phosphorylates dysbindin-1A at Serine 10 to regulate neuronal development. Neuroscience 490, 66&#x2013;78 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35124166</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickman D. K., Davis G. W., The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science 326, 1127&#x2013;1130 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063306</ArticleId><ArticleId IdType="pubmed">19965435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., et al. , Dysbindin-1, WAVE2 and Abi-1 form a complex that regulates dendritic spine formation. Mol. Psychiatry 15, 976&#x2013;986 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20531346</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J. M., Hu Z., Nordman J., Li Z., The schizophrenia susceptibility gene dysbindin regulates dendritic spine dynamics. J. Neurosci. 34, 13725&#x2013;13736 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188970</ArticleId><ArticleId IdType="pubmed">25297099</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanacora G., et al. , Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen. Psychiatry 56, 1043&#x2013;1047 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10565505</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah C. G., et al. , Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur. Neuropsychopharmacol. 25, 1082&#x2013;1090 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526377</ArticleId><ArticleId IdType="pubmed">25983019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanacora G., et al. , Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 61, 705&#x2013;713 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15237082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanacora G., Mason G. F., Rothman D. L., Krystal J. H., Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am. J. Psychiatry 159, 663&#x2013;665 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11925309</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubin M. J., et al. , Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. J. Psychiatry Neurosci. 41, E37&#x2013;E45 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4853214</ArticleId><ArticleId IdType="pubmed">26900793</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanacora G., et al. , Increased cortical GABA concentrations in depressed patients receiving ECT. Am. J. Psychiatry 160, 577&#x2013;579 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12611844</ArticleId></ArticleIdList></Reference><Reference><Citation>Milak M. S., et al. , A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol. Psychiatry 21, 320&#x2013;327 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758914</ArticleId><ArticleId IdType="pubmed">26283639</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine G. W., et al. , The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 191, 122&#x2013;127 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061550</ArticleId><ArticleId IdType="pubmed">21232924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosal S., et al. , Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the prefrontal cortex in male rodents. Neurobiol. Dis. 134, 104669&#x2013;104669 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31707118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z., et al. , Bidirectional homeostatic regulation of a depression-related brain state by gamma-aminobutyric acidergic deficits and ketamine treatment. Biol. Psychiatry 80, 457&#x2013;468 (2016), 10.1016/j.biopsych.2016.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2016.02.009</ArticleId><ArticleId IdType="pmc">PMC4983262</ArticleId><ArticleId IdType="pubmed">27062563</ArticleId></ArticleIdList></Reference><Reference><Citation>Fee C., Banasr M., Sibille E., Somatostatin-positive gamma-aminobutyric acid interneuron deficits in depression: Cortical microcircuit and therapeutic perspectives. Biol. Psychiatry 82, 549&#x2013;559 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610074</ArticleId><ArticleId IdType="pubmed">28697889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu C. Q., et al. , Compartmentalization of GABAergic inhibition by dendritic spines. Science 340, 759&#x2013;762 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752161</ArticleId><ArticleId IdType="pubmed">23661763</ArticleId></ArticleIdList></Reference><Reference><Citation>Higley M. J., Localized GABAergic inhibition of dendritic Ca(2+) signalling. Nat. Rev. Neurosci. 15, 567&#x2013;572 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383162</ArticleId><ArticleId IdType="pubmed">25116141</ArticleId></ArticleIdList></Reference><Reference><Citation>Banasr M., et al. , Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression. Chronic Stress (Thousand Oaks) 1, 2470547017720459 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5565173</ArticleId><ArticleId IdType="pubmed">28835932</ArticleId></ArticleIdList></Reference><Reference><Citation>Fee C., et al. , Behavioral deficits induced by somatostatin-positive GABA neuron silencing are rescued by alpha 5 GABA-A receptor potentiation. Int. J. Neuropsychopharmacol. 24, 505&#x2013;518 (2021), 10.1093/ijnp/pyab002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyab002</ArticleId><ArticleId IdType="pmc">PMC8278801</ArticleId><ArticleId IdType="pubmed">33438026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson S. T., et al. , Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: A randomized clinical trial. Psychother. Psychosom. 90, 318&#x2013;327 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34186531</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., et al. , Fear conditioning and extinction induce opposing changes in dendritic spine remodeling and somatic activity of layer 5 pyramidal neurons in the mouse motor cortex. Sci. Rep. 9, 4619 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420657</ArticleId><ArticleId IdType="pubmed">30874589</ArticleId></ArticleIdList></Reference><Reference><Citation>Chekroud S. R., et al. , Association between physical exercise and mental health in 1.2 million individuals in the USA between 2011 and 2015: A cross-sectional study. Lancet Psychiatry 5, 739&#x2013;746 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30099000</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau S. Y., et al. , Sustained running in rats administered corticosterone prevents the development of depressive behaviors and enhances hippocampal neurogenesis and synaptic plasticity without increasing neurotrophic factor levels. Cell Trans. 23, 481&#x2013;492 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24816445</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter M. W., Stevens B., Microglia emerge as central players in brain disease. Nat. Med. 23, 1018&#x2013;1027 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., et al. , Enriched environment ameliorates learning and memory deficits in hepatic encephalopathy mice by restoration of the structure of dendrites and dendritic spines. Brain Res. 1804, 148264 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36702182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamidi N., Yap C. G., Nayak N., Environmental enrichment preserves hippocampal neurons in diabetes and stressed rats. Histol. Histopathol. 37, 385&#x2013;395 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34978332</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashokan A., Hegde A., Mitra R., Short-term environmental enrichment is sufficient to counter stress-induced anxiety and associated structural and molecular plasticity in basolateral amygdala. Psychoneuroendocrinology 69, 189&#x2013;196 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27128967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X. L., Bergstr&#xf6;m S. A., Brink M., R&#xf6;nnb&#xe4;ck A., Dahlqvist P., Enriched environment increases spinophilin mRNA expression and spinophilin immunoreactive dendritic spines in hippocampus and cortex. Neurosci. Lett. 476, 79&#x2013;83 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20385205</ArticleId></ArticleIdList></Reference><Reference><Citation>Landers M. S., Knott G. W., Lipp H. P., Poletaeva I., Welker E., Synapse formation in adult barrel cortex following naturalistic environmental enrichment. Neuroscience 199, 143&#x2013;152 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22061424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Rodr&#xed;guez G., et al. , Environmental enrichment induces neuroplastic changes in middle age female Balb/c mice and increases the hippocampal levels of BDNF, p-Akt and p-MAPK1/2. Neuroscience 260, 158&#x2013;170 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24361917</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rtig W., Brauer K., Br&#xfc;ckner G., Wisteria floribunda agglutinin-labelled nets surround parvalbumin-containing neurons. Neuroreport 3, 869&#x2013;872 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1421090</ArticleId></ArticleIdList></Reference><Reference><Citation>Donegan J. J., Lodge D. J., Hippocampal perineuronal nets are required for the sustained antidepressant effect of ketamine. Int. J. Neuropsychopharmacol. 20, 354&#x2013;358 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578802</ArticleId><ArticleId IdType="pubmed">27806991</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuszko G., Curreli S., Kaushik R., Becker A., Dityatev A., Extracellular matrix alterations in the ketamine model of schizophrenia. Neuroscience 350, 13&#x2013;22 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28323012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik R., et al. , Fine structure analysis of perineuronal nets in the ketamine model of schizophrenia. Eur. J. Neurosci. 53, 3988&#x2013;4004 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32510674</ArticleId></ArticleIdList></Reference><Reference><Citation>Venturino A., et al. , Microglia enable mature perineuronal nets disassembly upon anesthetic ketamine exposure or 60-Hz light entrainment in the healthy brain. Cell Rep. 36, 109313 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284881</ArticleId><ArticleId IdType="pubmed">34233180</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah C. G., et al. , Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology 45, 990&#x2013;997 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162891</ArticleId><ArticleId IdType="pubmed">32092760</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., et al. , mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. J. Immunol. 192, 6009&#x2013;6019 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128178</ArticleId><ArticleId IdType="pubmed">24829408</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshmit Y., et al. , Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury. Mol. Cell Neurosci. 68, 82&#x2013;91 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25936601</ArticleId></ArticleIdList></Reference><Reference><Citation>Guden D. S., et al. , mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by lipopolysaccharide challenge in rats. Can J. Physiol. Pharmacol. 99, 921&#x2013;934 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33641344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai J., et al. , Exercise facilitates the M1-to-M2 polarization of microglia by enhancing autophagy via the BDNF/AKT/mTOR pathway in neuropathic pain. Pain Phys. 25, E1137&#x2013;E1151 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36288601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., et al. , Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway. J. Neuroimmunol. 299, 164&#x2013;171 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27725116</ArticleId></ArticleIdList></Reference><Reference><Citation>He T., et al. , Sestrin2 regulates microglia polarization through mTOR-mediated autophagic flux to attenuate inflammation during experimental brain ischemia. J. Neuroinflammation 17, 329 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643276</ArticleId><ArticleId IdType="pubmed">33153476</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., et al. , mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. FASEB J. 30, 3388&#x2013;3399 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27342766</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X. G., et al. , Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol. Carcinog. 49, 603&#x2013;610 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20512842</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares H. P., Ni Y., Kisfalvi K., Sinnett-Smith J., Rozengurt E., Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One 8, e57289 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578870</ArticleId><ArticleId IdType="pubmed">23437362</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston J. N., et al. , Inflammation, stress and depression: An exploration of ketamine&#x2019;s therapeutic profile. Drug Discov. Today 28, 103518 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050119</ArticleId><ArticleId IdType="pubmed">36758932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkman H. O., Inhibition of microglial GSK3&#x3b2; activity is common to different kinds of antidepressants: A proposal for an in vitro screen to detect novel antidepressant principles. Biomedicines 11, 806 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10045655</ArticleId><ArticleId IdType="pubmed">36979785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Ding X., Wu X., Huang S., Ketamine inhibits LPS-mediated BV2 microglial inflammation via NMDA receptor blockage. Fundam. Clin. Pharmacol. 34, 229&#x2013;237 (2019), 10.1111/fcp.12508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12508</ArticleId><ArticleId IdType="pubmed">31514224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M.-F., Zhang C., Zhang L., Li H., Weinshilboum R. M., Ketamine and active ketamine metabolites regulate STAT3 and the Type I interferon pathway in human microglia: Molecular mechanisms linked to the antidepressant effects of ketamine. Front Pharmacol. 10, 1302&#x2013;1302 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6848891</ArticleId><ArticleId IdType="pubmed">31827434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M., et al. , Ketamine regulates the autophagy flux and polarization of microglia through the HMGB1-RAGE axis and exerts antidepressant effects in mice. J. Neuropathol. Exp. Neurol. 81, 931&#x2013;942 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35582883</ArticleId></ArticleIdList></Reference><Reference><Citation>Su T. P., et al. , Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42, 2482&#x2013;2492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686503</ArticleId><ArticleId IdType="pubmed">28492279</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava M., et al. , Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol. Psychiatry 25, 1592&#x2013;1603 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447473</ArticleId><ArticleId IdType="pubmed">30283029</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah C. G., et al. , Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 47, 1574&#x2013;1581 (2022), 10.1038/s41386-022-01266-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-022-01266-9</ArticleId><ArticleId IdType="pmc">PMC8767037</ArticleId><ArticleId IdType="pubmed">35046508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth N. J., Sepehry A. A., Vila-Rodriguez F., Effects of ketamine anesthesia on efficacy, tolerability, seizure response, and neurocognitive outcomes in electroconvulsive therapy: A comprehensive meta-analysis of double-blind randomized controlled trials. J. ECT 36, 94&#x2013;105 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31725054</ArticleId></ArticleIdList></Reference><Reference><Citation>Casarotto P. C., et al. , Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell 184, 1299&#x2013;1313.e1219 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938888</ArticleId><ArticleId IdType="pubmed">33606976</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghaddam B., Adams B., Verma A., Daly D., Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921&#x2013;2927 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573099</ArticleId><ArticleId IdType="pubmed">9092613</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis N. A., Berry S. C., Burton N. R., Lodge D., The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. British J. Pharmacol. 79, 565&#x2013;575 (1983).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2044888</ArticleId><ArticleId IdType="pubmed">6317114</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., et al. , Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine. Sci. Signal 9, ra123 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564288</ArticleId><ArticleId IdType="pubmed">27965425</ArticleId></ArticleIdList></Reference><Reference><Citation>Orser B. A., Pennefather P. S., MacDonald J. F., Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 86, 903&#x2013;917 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9105235</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke R. J., Glasgow N. G., Johnson J. W., Mechanistic and structural determinants of NMDA receptor voltage-dependent gating and slow Mg2+ unblock J. Neurosci. 33, 4140&#x2013;4150 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629906</ArticleId><ArticleId IdType="pubmed">23447622</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow N. G., Siegler Retchless B., Johnson J. W., Molecular bases of NMDA receptor subtype-dependent properties. J. Physiol. 593, 83&#x2013;95 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293056</ArticleId><ArticleId IdType="pubmed">25556790</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow N. G., Wilcox M. R., Johnson J. W., Effects of Mg(2+) on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site. Neuropharmacology 137, 344&#x2013;358 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050087</ArticleId><ArticleId IdType="pubmed">29793153</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava M., et al. , Esmethadone-HCl (REL-1017): A promising rapid antidepressant. Eur. Arch Psychiatry Clin. Neurosci. 273, 1463&#x2013;1476 (2023), 10.1007/s00406-023-01571-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-023-01571-4</ArticleId><ArticleId IdType="pmc">PMC10465385</ArticleId><ArticleId IdType="pubmed">36890259</ArticleId></ArticleIdList></Reference><Reference><Citation>De Gregorio D., et al. , Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc. Natl. Acad. Sci. U.S.A. 118, e2020705118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7865169</ArticleId><ArticleId IdType="pubmed">33495318</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleksandrova L. R., Phillips A. G., Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol. Sci. 42, 929&#x2013;942 (2021), 10.1016/j.tips.2021.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2021.08.003</ArticleId><ArticleId IdType="pubmed">34565579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan A. C., Olson D. E., Preller K. H., Roth B. L., The neural basis of psychedelic action. Nat. Neurosci. 25, 1407&#x2013;1419 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9641582</ArticleId><ArticleId IdType="pubmed">36280799</ArticleId></ArticleIdList></Reference><Reference><Citation>Carhart-Harris R., et al. , Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402&#x2013;1411 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33852780</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin G. M., et al. , Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637&#x2013;1648 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36322843</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin G. M., et al. , Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J. Affect Disord 327, 120&#x2013;127 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36740140</ArticleId></ArticleIdList></Reference><Reference><Citation>Preskorn S. H., et al. , An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28, 631&#x2013;637 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19011431</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N., et al. , Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754&#x2013;761 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068225</ArticleId><ArticleId IdType="pubmed">21292242</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;pper M., et al. , GluN2B inhibition rescues impaired potentiation and epileptogenicity at associational-commissural CA3 synapses in a model of anti-NMDAR encephalitis. Neurosci. Lett. 795, 137031 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36574811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridi M. C. D., et al. , Two distinct mechanisms for experience-dependent homeostasis. Nat. Neurosci. 21, 843&#x2013;850 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6019646</ArticleId><ArticleId IdType="pubmed">29760525</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller O. H., Moran J. T., Hall B. J., Two cellular hypotheses explaining the initiation of ketamine&#x2019;s antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology 100, 17&#x2013;26 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26211972</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller O. H., et al. , GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife 3, e03581 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270067</ArticleId><ArticleId IdType="pubmed">25340958</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamsson T., et al. , Differential regulation of evoked and spontaneous release by presynaptic NMDA receptors. Neuron 96, 839&#x2013;855.e835 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29033205</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate C. A. Jr., et al. , A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 163, 153&#x2013;155 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16390905</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsaad H. A., et al. , In the telencephalon, GluN2C NMDA receptor Subunit mRNA is predominately expressed in glial cells and GluN2D mRNA in interneurons. Neurochem. Res. 44, 61&#x2013;77 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349034</ArticleId><ArticleId IdType="pubmed">29651654</ArticleId></ArticleIdList></Reference><Reference><Citation>Garst-Orozco J., et al. , GluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneurons. PLoS One 15, e0233895 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272025</ArticleId><ArticleId IdType="pubmed">32497062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S. C., et al. , The NMDA receptor GluN2C subunit controls cortical excitatory-inhibitory balance, neuronal oscillations and cognitive function. Sci. Rep. 6, 38321 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138829</ArticleId><ArticleId IdType="pubmed">27922130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson E., et al. , Tonic activation of GluN2C/GluN2D-containing NMDA receptors by ambient glutamate facilitates cortical interneuron maturation. J. Neurosci. 39, 3611&#x2013;3626 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510335</ArticleId><ArticleId IdType="pubmed">30846615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikrishnan A., et al. , Region-specific expression of NMDA receptor GluN2C Subunit in parvalbumin-positive neurons and astrocytes: Analysis of GluN2C expression using a novel reporter model. Neuroscience 380, 49&#x2013;62 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086378</ArticleId><ArticleId IdType="pubmed">29559384</ArticleId></ArticleIdList></Reference><Reference><Citation>Han D. H., et al. , Abolished ketamine effects on the spontaneous excitatory postsynaptic current of medial prefrontal cortex neurons in GluN2D knockout mice. Mol. Brain 14, 174 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8650376</ArticleId><ArticleId IdType="pubmed">34876180</ArticleId></ArticleIdList></Reference><Reference><Citation>Foga&#xe7;a M. V., et al. , N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology 44, 2230&#x2013;2238 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898593</ArticleId><ArticleId IdType="pubmed">31454827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava M., et al. , REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: A phase 2a randomized double-blind trial. Am. J. Psychiatry 179, 122&#x2013;131 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34933568</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlestova E., Johnson J. W., Krystal J. H., Lisman J., The role of GluN2C-containing NMDA receptors in ketamine&#x2019;s psychotogenic action and in Schizophrenia models. J. Neurosci. 36, 11151&#x2013;11157 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5148234</ArticleId><ArticleId IdType="pubmed">27807157</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarr&#xe9;s-Gatius M., Miquel-Rio L., Campa L., Artigas F., Casta&#xf1;&#xe9; A., Involvement of NMDA receptors containing the GluN2C subunit in the psychotomimetic and antidepressant-like effects of ketamine. Transl. Psychiatry 10, 427 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7729946</ArticleId><ArticleId IdType="pubmed">33303736</ArticleId></ArticleIdList></Reference><Reference><Citation>Trullas R., Ginter H., Skolnick P., A benzodiazepine receptor inverse agonist inhibits stress-induced ulcer formation. Pharmacol. Biochem. Behav. 27, 35&#x2013;39 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3039540</ArticleId></ArticleIdList></Reference><Reference><Citation>Braestrup C., Nielsen M., Honore T., Jensen L. H., Petersen E. N., Benzodiazepine receptor ligands with positive and negative efficacy. Neuropharmacology 22, 1451&#x2013;1457 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6322039</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo B., et al. , Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J. Neurogenet. 25, 152&#x2013;166 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22091727</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimizu T., Shimazaki T., Ito A., Chaki S., An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 186, 587&#x2013;593 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16612616</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkesman O., et al. , Acute D-serine treatment produces antidepressant-like effects in rodents. Int. J. Neuropsychopharmacol. 15, 1135&#x2013;1148 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278496</ArticleId><ArticleId IdType="pubmed">21906419</ArticleId></ArticleIdList></Reference><Reference><Citation>Heresco-Levy U., et al. , A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol. 16, 501&#x2013;506 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23174090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.-H., et al. , Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: A double-blind randomized placebo-control study. Neuropsychopharmacology 44, 2112&#x2013;2118 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898334</ArticleId><ArticleId IdType="pubmed">31421635</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilc A., Machaczka A., Kawalec P., Smith J. L., Witkin J. M., Where do we go next in antidepressant drug discovery? A new generation of antidepressants: A pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opin. Drug Discov. 17, 1131&#x2013;1146 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35934973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadriu B., et al. , Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road. Drug Discov. Today 26, 2816&#x2013;2838 (2021), 10.1016/j.drudis.2021.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.07.027</ArticleId><ArticleId IdType="pmc">PMC9585480</ArticleId><ArticleId IdType="pubmed">34358693</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis-Reyes B. D., et al. , Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats. Behav. Pharmacol. 32, 335&#x2013;344 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119302</ArticleId><ArticleId IdType="pubmed">33595955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauterborn J. C., Lynch G., Vanderklish P., Arai A., Gall C. M., Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20, 8&#x2013;21 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774091</ArticleId><ArticleId IdType="pubmed">10627576</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta S., et al. , Discovery of NV-5138, the first selective Brain mTORC1 activator. Sci. Rep. 9, 4107 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6412019</ArticleId><ArticleId IdType="pubmed">30858438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T., et al. , Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J. Clin. Invest. 129, 2542&#x2013;2554 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546461</ArticleId><ArticleId IdType="pubmed">30990795</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R. J., et al. , GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 38, 2268&#x2013;2277 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773678</ArticleId><ArticleId IdType="pubmed">23680942</ArticleId></ArticleIdList></Reference><Reference><Citation>E. o. t. M. Letter, Dextromethorphan/bupropion (Auvelity) for depression. Med. Lett. Drugs Ther. 64, 201&#x2013;203 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36542346</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A., et al. , Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry 57, 270&#x2013;276 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10711913</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., et al. , Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) 135, 213&#x2013;229 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9498724</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupitsky E. M., et al. , Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: Psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 25, 936&#x2013;947 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11750186</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., et al. , Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179, 303&#x2013;309 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15309376</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber N. B., Jiang X. P., Heinkel C., Nemmers B., Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol. Psychiatry 7, 726&#x2013;733 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12192617</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody S. A., Geyer M. A., Large C. H., Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169, 240&#x2013;246 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12698229</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakao S., et al. , Halothane and diazepam inhibit ketamine-induced c-fos expression in the rat cingulate cortex. Anesthesiology 85, 874&#x2013;882 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8873559</ArticleId></ArticleIdList></Reference><Reference><Citation>Homayoun H., Jackson M. E., Moghaddam B., Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J. Neurophysiol. 93, 1989&#x2013;2001 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15590730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y. M., Zhang J. T., Zhao F. Q., Li F., Effects of nimodipine on l-glutamate-induced seizures and Ca2+ influx in hippocampus in freely moving rats. Zhongguo Yao Li Xue Bao 12, 297&#x2013;300 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1807075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp F. R., et al. , Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 62, 1079&#x2013;1092 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7845588</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra A. K., et al. , Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol. Psychiatry 42, 664&#x2013;668 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9325559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahti A. C., Koffel B., LaPorte D., Tamminga C. A., Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9&#x2013;19 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8526975</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., et al. , Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145, 193&#x2013;204 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10463321</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza D. C., et al. , Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence. Neuropsychopharmacology 37, 1036&#x2013;1046 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280648</ArticleId><ArticleId IdType="pubmed">22113087</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza D. C., et al. , Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and Schizophrenia subjects. Biol. Psychiatry 84, 413&#x2013;421 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068006</ArticleId><ArticleId IdType="pubmed">29499855</ArticleId></ArticleIdList></Reference><Reference><Citation>Roxas N., Ahuja C., Isom J., Wilkinson S. T., Capurso N., A potential case of acute ketamine withdrawal: Clinical implications for the treatment of refractory depression. Am. J. Psychiatry 178, 588&#x2013;591 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34270337</ArticleId></ArticleIdList></Reference><Reference><Citation>Schak K. M., et al. , Potential risks of poorly monitored ketamine use in depression treatment. Am. J. Psychiatry 173, 215&#x2013;218 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26926127</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan C. J., Monaghan L., Curran H. V., Beyond the K-hole: A 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction (Abingdon, England) 99, 1450&#x2013;1461 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15500598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakura T., Harris R. A., Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 93, 1095&#x2013;1101 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11020766</ArticleId></ArticleIdList></Reference><Reference><Citation>van Amsterdam J. G., Nabben T., van den Brink W., Increasing recreational nitrous oxide use: Should we worry? A narrative review. J. Psychopharmacol. 36, 943&#x2013;950 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35678512</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray S., Brewerton T., Abuse of over-the-counter dextromethorphan by teenagers. South Med. J. 86, 1151&#x2013;1153 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8211334</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis B. L., The PCP epidemic: A critical review. Int. J. Addict 17, 1137&#x2013;1155 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6757154</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., Petrakis I. L., Mason G., Trevisan L., D&#x2019;Souza D. C., N-methyl-D-aspartate glutamate receptors and alcoholism: Reward, dependence, treatment, and vulnerability. Pharmacol. Ther. 99, 79&#x2013;94 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12804700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura J., et al. , Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability. Mol. Psychiatry 26, 6704&#x2013;6722 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8517038</ArticleId><ArticleId IdType="pubmed">33859356</ArticleId></ArticleIdList></Reference><Reference><Citation>Madonick S. M., et al. , Naltrexone blockade of ketamine intoxication in healthy humans. Alcoholism: Clin. Exp. Res. 23, 103A (1999).</Citation></Reference><Reference><Citation>Williams N. R., et al. , Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am. J. Psychiatry 175, 1205&#x2013;1215 (2018), 10.1176/appi.ajp.2018.18020138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2018.18020138</ArticleId><ArticleId IdType="pmc">PMC6395554</ArticleId><ArticleId IdType="pubmed">30153752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon G., Petrakis I. L., Krystal J. H., Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry 76, 337&#x2013;338 (2019), 10.1001/jamapsychiatry.2018.3990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2018.3990</ArticleId><ArticleId IdType="pmc">PMC6439824</ArticleId><ArticleId IdType="pubmed">30624551</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M. E., Chandra J., Sheriff S., Malinow R., Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc. Natl. Acad. Sci. U.S.A. 117, 2656&#x2013;2662 (2020), 10.1073/pnas.1916570117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1916570117</ArticleId><ArticleId IdType="pmc">PMC7007545</ArticleId><ArticleId IdType="pubmed">31941713</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek G. J., Wright R. A., Schoepp D. D., Monn J. A., Aghajanian G. K., Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther 292, 76&#x2013;87 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10604933</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoudian P. A., Shao L. X., Kwan A. C., Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem. Neurosci. 14, 468&#x2013;480 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9898239</ArticleId><ArticleId IdType="pubmed">36630309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron L. P., et al. , A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589, 474&#x2013;479 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7874389</ArticleId><ArticleId IdType="pubmed">33299186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumpper R. H., Roth B. L., Psychedelics: Preclinical insights provide directions for future research. Neuropsychopharmacology (2023), 10.1038/s41386-023-01567-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-023-01567-7</ArticleId><ArticleId IdType="pmc">PMC10700551</ArticleId><ArticleId IdType="pubmed">36932180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis V., et al. , A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 42, 112203 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10112881</ArticleId><ArticleId IdType="pubmed">36884348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzel K. H., Mayer-Gross W., Prevention of psychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148). Nature 178, 210 (1956).</Citation><ArticleIdList><ArticleId IdType="pubmed">13348662</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark L. D., Bliss E. L., Psychopharmacological studies of lysergic acid diethylamide (LSD-25) intoxication; effects of premedication with BOL-128 (2-bromo-d-lysergic acid diethylamide), mescaline, atropine, amobarbital, and chlorpromazine. AMA Arch Neurol. Psychiatry 78, 653&#x2013;655 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13478222</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao L. X., et al. , Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535&#x2013;2544.e4 (2021), 10.1016/j.neuron.2021.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.06.008</ArticleId><ArticleId IdType="pmc">PMC8376772</ArticleId><ArticleId IdType="pubmed">34228959</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblat J. D., Leon-Carlyle M., Ali S., Husain M. I., McIntyre R. S., Antidepressant effects of psilocybin in the absence of psychedelic effects. Am. J. Psychiatry 1820, 395&#x2013;396 (2023), 10.1176/appi.ajp.20220835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.20220835</ArticleId><ArticleId IdType="pubmed">36945824</ArticleId></ArticleIdList></Reference><Reference><Citation>Case B. G., et al. , Declining use of electroconvulsive therapy in United States general hospitals. Biol. Psychiatry 73, 119&#x2013;126 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5375110</ArticleId><ArticleId IdType="pubmed">23059049</ArticleId></ArticleIdList></Reference><Reference><Citation>G. B. o. D. Study, Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990&#x2013;2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9, 137&#x2013;150 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776563</ArticleId><ArticleId IdType="pubmed">35026139</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaynes B. N., et al. , What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 60, 1439&#x2013;1445 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19880458</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller M. B., et al. , Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch. Gen. Psychiatry 49, 809&#x2013;816 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1417434</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>